Author

Kathy Puyana Theall

Observed names: K Puyana Theall, K. Puyana Theall, K.Puyana Theall, Kathy Puvana Theall, Kathy Puyana

Observed institutions: Sunnybrook Health Science Centre, Seoul National University, Thomas Jefferson University, University of California, Los Angeles, The University of Melbourne, Pfizer (United States), Peter MacCallum Cancer Centre, Seoul National University Hospital, Osaka National Hospital, Menarini Group (Italy), National Cancer Center, Royal Marsden Hospital, Stemline Therapeutics (United States), European Institute of Oncology, University of Pennsylvania

OpenAlex ID: A5113726180

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 · Massimo Cristofanilli, Nicholas C Turner, et al. · The Lancet Oncology · 1,817

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 · Nicholas C. Turner, Dennis J. Slamon, et al. · New England Journal of Medicine · 1,273

PDF

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

2021 · Erica L Mayer, Amylou C Dueck, et al. · The Lancet Oncology · 261

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

2016 · N. Harbeck, S. Iyer, et al. · Annals of Oncology · 176

PDF

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

2017 · Sibylle Loibl, Nicholas C. Turner, et al. · The Oncologist · 154

PDF

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3

2018 · Massimo Cristofanilli, Angela DeMichele, et al. · European Journal of Cancer · 75

PDF

Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up

2021 · Richard S. Finn, Hope S. Rugo, et al. · The Oncologist · 60

PDF

Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3

2021 · Hope S. Rugo, Massimo Cristofanilli, et al. · The Oncologist · 33

PDF

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

2020 · E.L. Mayer, M.I. Gnant, et al. · Annals of Oncology · 29

PDF

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

2019 · Karen A. Gelmon, Massimo Cristofanilli, et al. · The Breast Journal · 12

PDF

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

2022 · Hope S. Rugo, Seock-Ah Im, et al. · The Breast · 11

PDF

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

2018 · M. Cristofanilli, D.J. Slamon, et al. · Annals of Oncology · 10

PDF

Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3.

2016 · Sibylle Loibl, Nicholas C. Turner, et al. · Journal of Clinical Oncology · 9

Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.

2024 · Hope S. Rugo, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 8

Abstract PS17-02: Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial

2024 · Aditya Bardia, Joyce O'Shaughnessy, et al. · Cancer Research · 8

Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.

2024 · Nuhad K. Ibrahim, Erika P. Hamilton, et al. · Journal of Clinical Oncology · 5

Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

2022 · Georg Pfeiler, Dominik Hlauschek, et al. · Journal of Clinical Oncology · 5

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

2025 · Nancy Chan, Virginia G. Kaklamani, et al. · Journal of Clinical Oncology · 4

The Effects of Adding Palbociclib to Endocrine Therapy to Treat Advanced Breast Cancer: A Plain Language Summary of a Study Using the PALOMA-2 and PALOMA-3 Trial Results

2023 · Hope S. Rugo, Seock-Ah Im, et al. · Future Oncology · 3

Efficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3

2017 · S-A Im, N. Masuda, et al. · Annals of Oncology · 3

Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

2025 · Hope S. Rugo, Sara M. Tolaney, et al. · Journal of Clinical Oncology · 2

PDF

Abstract CT074: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

2024 · Erika Hamilton, Sung-Bae Kim, et al. · Cancer Research · 2

Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials

2023 · Sibylle Loibl, Carsten Denkert, et al. · Cancer Research · 2

Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.

2017 · Massimo Cristofanilli, Angela DeMichele, et al. · Journal of Clinical Oncology · 2

Abstract PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC)

2025 · Hope S. Rugo, Sara M. Tolaney, et al. · Clinical Cancer Research · 1

Works count: 40

Citation count: 3,971

H-index: 11

I10-index: 12